HealthyEarly Phase 1NCT05153395
Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation
A Early Phase 1 study testing Carbon dioxide breathing, Neurovascular Coupling and Human insulin in people with Healthy and Vasodilation, run by University of Missouri-Columbia at 1 site in United States.
Trial summary
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Vasodilation, Insulin Resistance
- What is being tested?
- Carbon dioxide breathing, Neurovascular Coupling and Human insulin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 65 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2021to Jun 2027
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy adult men and women;
- 18-45 years of age;
- BMI >18 kg/m2;
- non-pregnant/non-breastfeeding;
- non-nicotine users;
Who cannot join
- taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic
- Self-reported history of:
- hepatic, renal, pulmonary, cardiovascular, or neurological disease;
- stroke or neurovascular disease;
- bleeding/clotting disorders;
- sleep apnea or other sleep disorders;
Show all 13Show fewer
- diabetes;
- smoking;
- history of alcoholism or substance abuse;
- hypertension;
- respiratory disease;
- active cancer;
- autoimmune disease.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Novel Treatment for Brain Insulin Resistance and Hypoperfusion
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.
- Conditions
- Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
- Being tested
- Carbon dioxide breathing, Neurovascular Coupling, Human insulin
- Medical subject headings
- Aneurysm, Insulin Resistance, Primary Dysautonomias, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Carbon dioxide breathingOther
Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.
Neurovascular CouplingOther
Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.
Human insulinDrug
Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.
| Study group | Role | What they receive |
|---|---|---|
| Insulin (Doppler) | Experimental | Human insulin (160 IU) will be administered as a bolus using an intra-nasal device. Receives: Other: Carbon dioxide breathing; Other: Neurovascular Coupling; Drug: Human insulin |
| Insulin (MRI) | Experimental | Human insulin (160 IU) will be administered as a bolus using an intra-nasal device. Receives: Other: Carbon dioxide breathing; Drug: Human insulin |
| Time Control (Doppler) | Other | Time control only Receives: Other: Carbon dioxide breathing; Other: Neurovascular Coupling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amount of cerebral blood flow
Measured with trans-cranial Doppler ultrasound (cm/s) or arterial spin labeling (mL/100 g/min)
Measured: Change from baseline at minute 15
Secondary outcomes (2)
Amount of muscle sympathetic nerve activity (MSNA)
MSNA burst incidence (bursts/100 heart beats)
Measured: Change from baseline at minute 15
Amount of leg blood flow
Measured with Doppler ultrasound (mL/min)
Measured: Change from baseline at minute 15
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2021
- Study start1 Dec 2021
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Why it stopped: Interim data and power analysis
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of Missouri-ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 65 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Missouri-Columbia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jacqueline K Limberg, PhD, University of Missouri-Columbia
- Investigators
- Jacqueline K Limberg, Ph.D., Principal investigator, University of Missouri-Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05153395
- Sponsor's protocol ID
- 2057288
- Status last verified
- Dec 2025
- First submitted
- 18 Nov 2021
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Novel Treatment for Brain Insulin Resistance and Hypoperfusion
- ClinicalTrials.gov ID
- NCT05153395
- Acronym / sponsor ID
- 2057288
- Conditions
- Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Interim data and power analysis
- Enrolment
- 65 participants (estimated)
- Lead sponsor
- University of Missouri-ColumbiaUniversity, hospital or other
- Study start
- 1 Dec 2021 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 10 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Insulin (Doppler) | Experimental | Other: Carbon dioxide breathing, Other: Neurovascular Coupling, Drug: Human insulinHuman insulin (160 IU) will be administered as a bolus using an intra-nasal device. |
| Insulin (MRI) | Experimental | Other: Carbon dioxide breathing, Drug: Human insulinHuman insulin (160 IU) will be administered as a bolus using an intra-nasal device. |
| Time Control (Doppler) | Other | Other: Carbon dioxide breathing, Other: Neurovascular CouplingTime control only |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- healthy adult men and women;
- 18-45 years of age;
- BMI >18 kg/m2;
- non-pregnant/non-breastfeeding;
- non-nicotine users;
Key exclusion criteria (13 listed)
- taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic
- hepatic, renal, pulmonary, cardiovascular, or neurological disease;
- stroke or neurovascular disease;
- bleeding/clotting disorders;
- sleep apnea or other sleep disorders;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Carbon dioxide breathingHypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure. | Other | Insulin (Doppler), Insulin (MRI), Time Control (Doppler) |
| Neurovascular CouplingParticipants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure. | Other | Insulin (Doppler), Time Control (Doppler) |
| Human insulinParticipants will be administered human insulin (160 IU) as a bolus using an intra-nasal device. | Drug | Insulin (Doppler), Insulin (MRI) |
Primary outcome
Amount of cerebral blood flow
Time frame: Change from baseline at minute 15
Measured with trans-cranial Doppler ultrasound (cm/s) or arterial spin labeling (mL/100 g/min)
2 secondary outcomes
Amount of muscle sympathetic nerve activity (MSNA)
Time frame: Change from baseline at minute 15
Amount of leg blood flow
Time frame: Change from baseline at minute 15
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jacqueline K Limberg, Ph.D. principal investigator
University of Missouri-Columbia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Carbon dioxide breathing, Neurovascular Coupling and Human insulin in people with Healthy and Vasodilation, run by University of Missouri-Columbia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amount of cerebral blood flow (time frame: Change from baseline at minute 15). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.